Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zhangjiang Group And Sundia MediTech To Promote New Pharmaceutical R&D Outsourcing Model

This article was originally published in PharmAsia News

Executive Summary

Zhangjiang Group and Sundia MediTech have signed a collaboration agreement on new drug R&D outsourcing. The latter will integrate CRO resources to provide full-stop services for new drug development. Zhangjiang will be the first in China to implement the intellectual property plus CRO plus venture capital model to target new drug development in the country. Scheduled for completion within four years, the platform will screen and support promising class I new drug innovation projects with IP rights, as well as establish a pool of independent experts and funds to form a full drug development chain. The fresh approach will accelerate the local rate of securing authentication from the College of American Pathologists, a prerequisite for entering the global CRO market. (Click here for more - Chinese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel